GSK's efimosfermin shows potential to improve liver fibrosis in Phase II MASH study

• GSK will present new liver-disease study data at AASLD’s Liver Meeting in Denver, Colorado, Nov. 5-9, 2026.
• Long-term Phase 3 results reinforce Hibsago’s benefit in chronic hepatitis B following its recent FDA approval.
• Upcoming presentations will examine sustained functional cure following treatment withdrawal, predictors of response and potential retreatment strategies.
• Phase 2 efimosfermin findings suggest potential fibrosis improvement in advanced metabolic dysfunction-associated steatohepatitis, including compensated cirrhosis.
• Efimosfermin remains under evaluation in Phase 3 trials targeting moderate-to-advanced fibrosis and compensated cirrhosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.